Gender Differences in Suicidal and Self-Harming Responses to Esketamine: A Real-World Retrospective Study
Vassilis Martiadis, Fabiola Raffone, Danilo Atripaldi, Serena Testa, Paolo Giunnelli, Rita Cerlino, Manlio Russo, Azzurra Martini, Enrico Pessina, Carlo Ignazio Cattaneo, Domenico De Berardis
Current Neuropharmacology October 20, 2025 DOI: 10.2174/011570159x392347250929114024 via OpenAlex
Summary
AI-generated from the abstractA single dose of esketamine quickly reduced suicidal thoughts and depression in people with treatment-resistant depression. Preliminary evidence suggests that men and women may respond differently, indicating that personalized treatment approaches could improve results. More research is needed to confirm these gender differences, examine long-term effects, and understand the biological reasons behind them.
Study at a glance
| Characteristics | Preliminary study Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Esketamine |
| Citations | 21 |
| Key finding | Esketamine rapidly improved suicidality and depression in treatment-resistant depression, with preliminary evidence of gender-specific responses. |
Abstract
Esketamine rapidly improved suicidality and depression in TRD, with preliminary evidence suggesting gender-specific responses, and highlighting the importance of tailored interventions to maximize outcomes. Further research is needed to confirm these differences, explore the long-term effects, and understand the underlying mechanisms.